

Hepatitis C Prior Authorization Initial Approval Checklist



Please use the following checklist to determine if an Ambetter from Superior HealthPlan member meets the clinical prior authorization guidelines for Hepatitis C Virus (HCV) treatment.

✓	Initial Approval Checklist (Must Meet All)
<input type="checkbox"/>	Diagnosis of chronic HCV infection as evidenced by detectable serum HCV RNA levels by quantitative assay in the last 6 months
<input type="checkbox"/>	<p>Confirmed HCV genotype is one of the following:</p> <ul style="list-style-type: none"> For treatment-naïve patients: genotypes 1, 2, 3, 4, 5 or 6. For patients treatment-experienced with interferon (IFN)/pegylated-interferon (pegIFN), ribavirin (RBV), and/or sofosbuvir only: genotypes 1, 2, 3, 4, 5 or 6. For patients treatment-experienced with either an NS5A inhibitor or an NS3/4A protease inhibitor: genotype 1. <p><i>Please note: Chart note documentation and copies of lab results are required.</i></p>
<input type="checkbox"/>	Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease specialist.
<input type="checkbox"/>	Patient age is ≥ 18 years.
<input type="checkbox"/>	Confirmation of Child-Pugh A status, if cirrhosis is present.
<input type="checkbox"/>	If contraindicated to Mavyret, member must use Epclusa® for applicable genotypes and treatment status, unless contraindicated or clinically significant adverse effects are experienced.
<input type="checkbox"/>	Life expectancy is ≥ 12 months with HCV treatment.
<input type="checkbox"/>	Documented sobriety from alcohol and illicit IV drugs for ≥ 6 months prior to starting therapy, if applicable.
<input type="checkbox"/>	Member is not treatment-experienced with both NS3/4A protease inhibitor AND NS5A inhibitors, such as combination therapies including, Technivie™, Viekira™ and Zepatier®.
<input type="checkbox"/>	Member agrees to participate in a medication adherence program.
<input type="checkbox"/>	Prescribed regimen is consistent with an FDA or AASLD-IDSA recommended regimen.